Niacin/lovastatin

Drug Profile

Niacin/lovastatin

Alternative Names: Advicor; KS 01022; Nicostatin; Nicotinic acid/lovastatin

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Kos Pharmaceuticals
  • Developer AbbVie
  • Class Antihyperlipidaemics; Naphthalenes; Nicotinic-acids; Vitamins
  • Mechanism of Action Cholesterol inhibitors; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hyperlipidaemia

Most Recent Events

  • 17 Aug 2011 Sepracor Pharmaceuticals is now called Sunovion Pharmaceuticals Canada
  • 03 Jun 2008 Oryx Pharmaceuticals has been acquired by Sepracor
  • 13 Dec 2006 Kos Pharmaceuticals has been acquired by Abbott Laboratories
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top